Scientific article
Open access

Chimiothérapie de maintenance : futile ou utile ?

Published inRevue médicale suisse, vol. 11, no. 475, p. 1103-1107
Publication date2015

In incurable diseases, maintenance therapy aims to prolong the response achieved through induction. The goal is to delay disease progression, thus prolonging survival. Two maintenance modalities are used. The first, called continuation maintenance, consists of continuing the same agent used in the initial treatment. The second, called switch-maintenance, introduces an early second line drug immediately after induction. Proving the superiority of a maintenance strategy implies a better outcome with the maintenance compared to the same therapeutic agent used upon disease progression. This benefit may be observed in terms of overall survival and/or quality of life.

  • Adenocarcinoma/drug therapy/pathology
  • Aged
  • Antibodies, Monoclonal, Murine-Derived/therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Cisplatin/administration & dosage
  • Glutamates/administration & dosage
  • Guanine/administration & dosage/analogs & derivatives
  • Humans
  • Lung Neoplasms/drug therapy/pathology
  • Lymphoma, Follicular/drug therapy/pathology
  • Maintenance Chemotherapy/psychology/utilization
  • Male
  • Medical Futility
  • Neoplasms/drug therapy
  • Pemetrexed
  • Quality of Life
  • Rituximab
Citation (ISO format)
FRIEDLAENDER, Alex, FERNANDEZ, Eugenio, DIETRICH, Pierre-Yves. Chimiothérapie de maintenance : futile ou utile ? In: Revue médicale suisse, 2015, vol. 11, n° 475, p. 1103–1107.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation11/28/2016 9:33:00 AM
First validation11/28/2016 9:33:00 AM
Update time03/15/2023 1:08:25 AM
Status update03/15/2023 1:08:24 AM
Last indexation01/16/2024 10:41:49 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack